Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Thrombovoren
- Development stage
- Unknown
- Lead developer
- PT Tunggal Idaman Abadi
- Modality
- Small Molecules
- Administration
- Topical
01
Overview
Thrombovoren is a topical combination emulgel containing diclofenac diethylamine and heparin sodium. Developed by Tunggal Idaman Abdi, it is formulated to treat acute blunt soft-tissue injuries, such as sprains, strains, and contusions, by addressing both pain and bruising simultaneously. Diclofenac diethylamine acts as a nonsteroidal anti-inflammatory drug (NSAID) that inhibits cyclooxygenase-1 (COX-1) and cyclooxygenase-2 (COX-2) to reduce pain and inflammation. Heparin sodium acts as an anticoagulant by binding to antithrombin-III, which accelerates the inhibition of coagulation factors like thrombin and factor Xa, thereby promoting the resolution of hematomas and bruising. Thrombovoren was approved and launched in Indonesia in 2026.
- Brand names
- ThrombovorenThrombovoren Emulgel
- Other names
- diclofenac diethylamine + heparin sodium
02
Targets
ATIII (Antithrombin III)F2 (Thrombin)F10 (Factor Xa)PGHS-1 (Prostaglandin G/H Synthase 1)PTGS2 (Prostaglandin-Endoperoxide Synthase 2)
Beyond the preview
Go deeper on Thrombovoren.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Thrombovoren.